NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

The race is under way to make faster, cheaper and better GLP-1 drugs that will go beyond reducing obesity levels to treating ...

GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to prioritise exercise when taking them ...

JM Financial is bullish on Mounjaro's success in India, citing its price advantage, higher efficiency and the country's large ...

A Fremont business owner was arrested on March 12 and charged with prescribing prescription drugs without a license and ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Ozempic, the Danish pharma giant Novo Nordisk's anti-diabetic drug, has had everyone's attention over the past year. The ...

In a recent video, Amy Schumer opened up about her experiences with weight loss medications, particularly Mounjaro and Ozempic, sparking discussions on the efficacy and side effects of these drugs.

While the weight loss results were impressive across the group, the cost and side effects remain important barriers for ...

Researchers assessed data from 16 million patients from 2006 to 2020 taking semaglutide-based drugs; the active ingredient in Wegovy.